Uterine cervical cancer develops after persistent HPV-infection, through detectable and treatable precancer (CIN). Over 80% of women get HPV during their lives, but little is known why only few get a CIN or cancer. Alterations of vaginal immune defense and microbiome have emerged as novel risk factors for a persistent HPV infection and development of cervical neoplasia.
Mild precancer lesions have high tendency to regress spontaneously, but several surgical methods exist to treat high-grade CIN. The treatment can increase the risk of preterm birth. On the other hand, if the treatment is not done deep enough, the risk of cervical cancer increases. Progression markers are needed.
We aim to: 1) investigate the association between CIN treatment and cervicovaginal microbiome and immune defence. 2) To study the clinical course of treated and untreated precancer and associated factors 3) Determine the comparative safety and efficacy of different surgical treatment techniques.